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ABSTRACT 
Chromoblastomycosis (CMB) is a polymorphic fungal disease that usually affects 
the lower limbs and manifests as verrucous nodules or plaques that may ulcerate. 
American Tegumentary Leishmaniasis (ATL) is an infectious parasitic disease 
caused by digenetic protozoa of the genus Leishmania sp. which affects the skin 
and/or mucous membranes of man and various species of wild and domestic 
animals. Both are part of the World Health Organization (WHO) neglected tropical 
diseases portfolio, mostly affecting economically vulnerable populations without 
adequate sanitation and in close contact with infectious vectors. We present the 
report of a 59-year-old male patient, referred to the Hospital Geral Público de 
Palmas (HGPP) in December 2017, carrying a positive result from a direct 
parasitological detection test for Leishmania sp., in addition to multiple previously 
biopsied lesions caused by CMB. It was observed that the patient had an 
important improvement of the CMB lesions with the use of amphotericin B in 
combination with itraconazole, thus demonstrating the role that the former can 
play in the therapy of this fungal disease.    
Keywords: Chromoblastomycosis; American Tegumentary leishmaniasis; 
Amphotericin B. 
 
RESUMO 
A cromoblastomicose (CBM) é uma doença fúngica polimórfica, que acomete 
normalmente os membros inferiores e que se manifesta como nódulos ou placas 
verrucosas que podem ulcerar. A leishmaniose tegumentar (LT) é uma doença 
infectoparasitária causada por protozoários digenéticos do gênero Leishmania sp. 
que acomete a pele e/ou mucosas do homem e de várias espécies de animais 
silvestres e domésticos. Ambas fazem parte do portfólio de doenças 
negligenciadas da Organização Mundial da Saúde (OMS), afetando em sua maioria 
pessoas economicamente vulneráveis, sem saneamento adequado e em contato 
próximo com vetores infecciosos. Apresentamos neste trabalho o relato de um 
paciente, masculino, 59 anos, encaminhado ao Hospital Geral Público de Palmas 
(HGPP) em dezembro de 2017, portando exame parasitológico direto positivo para 
Leishmania sp., além de múltiplas lesões causadas por CBM previamente 
biopsiadas. Foi observado que o paciente teve importante melhora das lesões de 
CBM com uso da anfotericina B em associação ao itraconazol, demonstrando o 
papel que essa droga pode exercer na terapêutica desta doença fúngica. 
Palavras-chave: Cromoblastomicose; Leishmaniose Tegumentar; Anfotericina B. 
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INTRODUCTION 
 
CHROMOBLASTOMYCOSIS 
 
Chromoblastomycosis (CMB) is a polymorphic fungal 
disease that normally affects the lower limbs and manifests as 
verrucous nodules or plaques that may ulcerate.
1
 The fungus’s 
entrance through the skin is usually by traumatic 
implantation.
1
 
A characteristic primary lesion is then formed at the 
inoculation site, followed by a chronic involvement of 
epidermis, dermis and subcutaneous tissue associated with a 
granulomatous, purulent and fibrotic reaction and a non-
protective humoral immune response. It can evolve with 
secondary infection, leading to lymphedema and 
elephantiasis. In some rare cases, lymphatic and 
hematogenous dissemination has been observed. In general, 
CMB lesions are recalcitrant and extremely difficult to 
eradicate, and may undergo neoplastic changes that lead to 
skin cancer and constitute a true therapeutic challenge.
1-3
 
The direct mycological test may find peculiar forms 
denominated shaped bodies, produced by the dematiaceous 
fungi. The most frequently isolated organisms are Fonsecaea 
pedrosoi, Phialophora verrucosa, Cladosporium carrioni and 
more rarely Rhinocladiella aquaspersa.
4
 
CMB was added to the World Health Organization 
(WHO) portfolio of neglected diseases in 2017.
5
 It is a disease 
of global impact, but more prevalent in tropical and 
subtropical regions, mainly in Brazil, Mexico, Cuba and the 
Dominican Republic. However, some cases in temperate 
regions have recently been reported.
2
 
The first case of CMB was reported by Rudolph, in 
1914, while describing the clinical findings of patients from 
Estrela do Sul, Minas Gerais.
3,6
 Terra et al created the term 
chromoblastomycosis in 1922, to distinguish a fungal infection 
from a verrucous dermatitis.
6
 
Because it is a mycosis of implantation, the host’s 
occupation seems to play a significant role.
3
 The fact that CMB 
is strongly associated with agricultural activities corroborates 
the occupational nature of this disease.
3
 Because rural 
activities are more commonly performed by adult men, this 
disease rarely occurs before adolescence, with most patients 
in the 40-50 age group.
3
 Adult male individuals are much more 
affected than women, in a proportion of 15:1.
7
 
Since CMB is not a disease of compulsory notification, 
the epidemiological data are derived from published cases and 
surveys.
3
 In Brazil, the Amazon region has been considered an 
endemic area and the estimated incidence rate is 3/100,000 
inhabitants.
2,3
 In the state of Tocantins, the occurance of 5,906 
cases is estimated (0.68% of the estimate for Brazil).
7
 
 
AMERICAN TEGUMENTARY LEISHMANIASIS 
 
American Tegumentary Leishmaniasis (ATL) is an 
infectious parasitic disease caused by digenetic protozoa of 
the genus Leishmania sp., which affects the skin and/or 
mucous membranes of man and of various species of wild and 
domestic animals. Depending on the species of Leishmania 
and the relationship of the parasite with its host, the disease 
may present different clinical forms (cutaneous, mucosal or 
mucocutaneous).
8,9
 
At least seven species of Leishmania sp. are 
responsible for causing human disease in Brazil. The 
tegumentary form is mainly caused by L. (V.) braziliensis, L. 
(V.) guyanensis and L. (L.) amazonensis. Rarely, it can be 
caused by L. (V.) lainsoni, L. (V.) naiffi and L. (V.) shawi. The 
visceral form of leishmaniasis is caused by L. (L.) chagasi.
10
 In 
Central America, the cutaneous manifestations of L. (L.) 
infantum chagasi are quite common, while in Brazil they are 
extremely rare.
11
 
The transmission of Leishmania sp. in the Americas 
occurs mainly through the bite of females of the genus 
Lutzomyia sp.. These females need blood for maturing their 
eggs, and suck many vertebrates, including amphibians, 
reptiles, birds and mammals, the latter reservoirs of 
Leishmania sp..
12
 
ATL is still considered by WHO as a neglected disease, 
affecting mostly people living in poverty, without adequate 
sanitation and in close contact with infectious vectors
5
, 
despite being estimated as the ninth largest cause of 
individual infectious disease.
13
 According to WHO estimates, 
leishmaniasis occurs in 88 countries and notification is 
compulsory in only 30 of these. About 90% of all reported ATL 
cases have occurred in only six countries: Iran, Saudi Arabia, 
Syria and Afghanistan in the Old World; Brazil and Peru, in the 
New World.
9,14
 
In the Americas, it occurs from the southern United 
States to northern Argentina, with important predominance in 
South America, where it comprises almost all countries except 
Uruguay and Chile.
5,8
 In Brazil, ATL has been registered in all 
states, initially caused by the intrusion of man in the wild 
cycle, up to the 1950s, through deforestation for agriculture, 
construction of roads and hydroelectric dams, and the 
installation of population clusters. Since then, new outbreaks 
have occurred in several states.
10,15
 In Tocantins, during the 
year of 2010, the incidence of ATL was 40.62/100,000 
inhabitants, while the incidence rate in Brazil was 
11.59/100,000 inhabitants.
16
 
ATL is a public health problem, not only in Brazil, but 
also in other countries, due to its high incidence, wide 
geographical distribution and also the possibility of evolving to 
destructive, disfiguring and disabling forms. It is believed that 
the numbers of reported ATL cases do not reliably reflect the 
disease’s evolution, either because of the patient's delay in 
searching for health care, the diagnostic difficulties or even 
failure in correctly reporting the cases. Still, the increasing 
number of new cases and the intensity with which the human 
being is reached is evident.
8,9
 
We present here the case of a patient referred to the 
Hospital Geral Público de Palmas (HGPP) for ATL treatment, 
with a previous diagnosis of CMB from another service. 
 
CASE 
 
A. P. S., male, 59 years old, caucasian, married, rural 
worker, from the municipality of Abreulândia, Tocantins (TO). 
He was referred to the HGPP in December 2017, with a 
positive parasitological test for Leishmania sp.. He reported 
onset of a pustular lesion in the middle third of the left leg, 30 
Revista de Patologia do Tocantins  2018; 5(1): 46-52.                             DOI: 10.20873/uft.2446-6492.2018v5n1p46 
Resstel et al. 
 
48 
 
Revista de Patologia do Tocantins, Vol. 5 No. 1, Abril 2018 
 
days prior to his arrival in the hospital, which progressed to 
two ulcerated lesions. The lesions were associated with 
pruritus, pain, purulent secretion and phlogistic signs. During 
this period, he reports apllying latex extracted from a sangra 
d’água plant (Croton urucurama) on the lesions, but no 
improvement was observed. 
The patient reported a weight loss of 20kg in 3 months. 
In addition, he reported pain, crepitus and post-rest rigidity in 
the left knee joint. He referred as comorbidities: Systemic 
Arterial Hypertension (SAH) with a 10-year evolution; gouty 
arthritis, two years ago; obesity and dyslipidemia. He reported 
continued use of atenolol, acetylsalicylic acid, nifedipine, 
hydrochlorothiazide, losartan, allopurinol, and simvastatin. He 
also reported living in a masonry house, in the rural area, with 
untreated water supply. He is a farmer, with high exposure to 
sun light, without the use of sunscreen, only wearing physical 
barriers. He refers following a hyperlipidic and hyperproteic 
diet and sporadic ingestion of alcoholic beverages. He denies 
smoking and use of other drugs.  
In the physical examination, at the time of hospital 
admission, the patient was in good general condition, with 
grade 2 obesity (BMI: 38.7 kg/m²). He presented gouty tophi 
located in the right metatarsophalangeal, ulnar-humeral and 
tibial-femoral joints. Crepitation was found in both knees, and 
he felt pain with mobilization of the left knee. 
He had two blackened ulcerated lesions in the middle 
third of the left leg, measuring approximately 7cm and 3cm 
(figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1 - Blackened ulcerated lesions in the left leg at 
hospital admission. 
 
It was also observed that the patient had multiple 
verrucous-crustous, serpiginous, pruritic and desquamative 
lesions, with an erythematous base, distributed in the right 
lower limb (Figure 2). He also had a single lesion with the 
same pattern on the left arm. He reported that such lesions 
began about 20 years ago, with progressive evolution, being 
diagnosed as CMB three years ago, by means of a biopsy. He 
also reports that in the last 3 years he has undergone 
treatment for CMB, using itraconazole (100 mg twice daily), 
cryotherapy with liquid nitrogen and terbinafine, with 
stabilization of lesion growth. However, he says he has 
abandoned treatment due to lack of financial conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2 - Verrucous-crustous lesions (CMB) in right lower 
limb at hospital admission 
 
Supplementary examinations at admission: 
hemoglobin: 14.3g/dL; hematocrit: 42%; platelets: 
250,000/mm³; leukocytes: 7900/mm³; serum creatinine: 2.7 
mg/dL; urea: 47.0 mg/dL; uric acid: 8.8 mg/dL; sodium: 128 
mmol/L; potassium: 4.6 mmol/L; blood glucose: 145 mg/dL; 
and PCR: 13.14 mg/L. Rapid tests for HIV, hepatitis B and C, 
syphilis and chagas disease were nonreactive. 
During hospitalization, ulnar thickening and sensitivity 
alteration was noted in the 4th finger bilaterally, with more 
pronounced involvement of the right side. Ultrasound 
examination showed bilateral ulnar thickening, with right joint 
effusion. A bacilloscopy (ZIEHL) was requested, which 
presented a negative result. 
Treatment for ATL with liposomal amphotericin B was 
instituted because of the patient’s age and his multiple 
comorbidities. The total dose initially programmed was 20 
mg/kg, reaching a final dosage of 2.4 grams. The medication 
was initiated with a 300 mg dose, with adequate 
photoprotection and slow administration (1-2 hours). 
After the third day of administration, the drug was 
discontinued due to worsening of the patient's renal function, 
despite the clinical improvement of both leishmaniasis and 
CMB lesions. Ultrasonography of the kidneys and urinary 
tracts demonstrated severe hydronephrosis on the right side. 
The patient was evaluated by the department of urology, 
which verified an irreversible loss of the right kidney, and 
decided to program a nephrectomy for another time and keep 
ambulatory monitoring until then. After the suspension of 
another nephrotoxic drug used by the patient, the allopurinol, 
the patient’s renal function improved. Because there was no 
substitute for allopurinol available at the hospital, treatment 
for gout was discontinued. There was a follow-up by the 
department of nutrition/nutrology, in order to control uric 
acid levels through a specific diet. 
The administration of liposomal amphotericin B was 
resumed 7 days after its suspension, at a dose of 250 mg/day. 
Four doses were administered, totaling 1900 mg. A new direct 
parasitological test for protozoa was performed after the 
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seventh dose of amphotericin B, demonstrating absence of 
the parasite, thus defining the end of treatment for the ATL. In 
addition to amphotericin B indicated for treatment of ATL, 
itraconazole at the dose of 200 mg twice daily for treatment of 
CMB was used. 
The department of oncology surgery contraindicated 
debridement of the lesions. A new biopsy of fragments of all 
the lesions was carried out in order to rule out a possible 
spinocellular carcinoma. The results were negative for 
malignancy, ratifying previous biopsy for CMB. 
He was discharged after 17 days of hospitalization with 
evident improvement in the appearance of both lesions 
(figures 3, 4 and 5) and programming for outpatient follow-up. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3 - Left Leg ATL Lesions at Hospital Discharge 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4 - CMB injury in right lower limb at hospital discharge 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 5 - CMB injury in left arm at hospital discharge 
 
DISCUSSION 
 
Chromoblastomycosis is characteristically a rare 
chronic skin disease that occurs due to a fungal infection. Its 
form of infection occurs, most of the times, due to a 
cutaneous trauma caused by an object contaminated by the 
fungus. 
The diagnosis of CMB should be made as early as 
possible in order to begin treatment before there is 
dissemination and complications; and so that it can be rapidly 
differentiated from other diseases such as cutaneous 
leishmaniasis, sporotrichosis, cutaneous tuberculosis, leprosy 
and psoriasis.
17
 In a study conducted by Correia et al
4
, the time 
between the appearance of the lesions and the diagnosis 
ranged from one month to 25 years, and 29.6% of the cases 
had less than four years of evolution. The mean time between 
onset of a lesion and its diagnosis was 87.25 months, with 
standard deviation (SD) of 77.74 months. The analysis of this 
variable in rural workers shows that the average time between 
onset of the lesion and its diagnosis was 109.33 months, with 
SD of 93.23 months, while in other occupations, it was 69.18 
months, with SD of 61.10 months. 
The diagnosis is based on culture and direct 
microscopic examination with histopathological biopsy study. 
For a better accuracy, biopsy of the lesion with a large number 
of black spots is recommended.
18
 In microscopy with 20% 
KOH, it is possible to observe multicellular microscopic 
structures (5 to 12 μm), with darkened and thickened walls, 
called medlar bodies (the fungal spores), which are 
pathognomonic of CMB. The finding of monoclonal infiltrates 
(macrophages and neutrophils) endorses the hypothesis.
17,19 
The histopathological study is characterized by 
pseudoepitheliomatous hyperplasia with intraepidermal 
abscess and Medlar bodies.
20
 Mycological culture is the 
diagnosis gold standard, since it is not only confirmatory, but 
also allows the isolation and study of the species of the 
infecting fungi.
18
 More advanced tests may aid in diagnosis, 
like polymerase chain reaction (PCR) or serological tests 
(ELISA). 
A long process that can be made by means of physical 
therapeutic methods, systemic therapy with antifungals or the 
combination of both characterizes the treatment of CMB. 
Itraconazole is the first-line therapy in systemic treatment, at 
a dose of 200-400 mg/day. Terbinafine is the second most 
frequently used antifungal agent, with a recommended dose 
of 250-500 mg/day. Both drugs may be used during a variable 
time. The response to terbinafine was similar to that of 
itraconazole.
21-23
 
There are studies that reveal that amphotericin B 
used in combination with flucytosine and terbinafine in the 
treatment of the disease may lead to its cure.
24,25
 However, 
due to the former’s high nephrotoxicity, it is impossible to use 
it for long periods, and intravenous administration associated 
with intralesional injections is recommended.
24
 
Physical methods include, mainly, surgery and 
cryotherapy. Conventional surgery (excisional biopsy) is the 
best among these treatments and is recommended in early 
stage lesions and when they are well delimited. Cryotherapy 
using liquid nitrogen is only recommended in cases of small 
lesions.
3 
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In situations of refractoriness or advanced disease, 
the combination of systemic and physical therapies can be 
used. But there is no strong evidence of superiority of the 
combination of two types of systemic therapy.
3
 
In this patient’s case, the systemic therapy was 
previously associated with the physical therapy, by an 
irregular institution of itraconazole 200 mg/day associated 
with cryotherapy with liquid nitrogen and terbinafine, 
obtaining only stabilization of the lesions. But, due to 
difficulties of financial adherence to the scheme, the 
treatment was abandoned before its end. 
During hospitalization, unlike what is reported as the 
recommended therapy in previous studies, a scheme that 
associated liposomal amphotericin B, totaling 1900 mg, with 
itraconazole 400 mg/day, was instituted. This strategy 
resulted in an evident clinical improvement of the lesions on 
the limbs, allowing an ambulatory follow-up. 
The CMB cure criteria are based on clinical, 
mycological and histological criteria. In the presence of 
complete resolution of lesions, absence of fungal elements at 
microscopy and negative culture, the dermatosis is considered 
cured. 
ATL is a complex disease transmitted by vectors and 
caused by protozoa of the genus Leishmania sp.. Its incubation 
period may take weeks to months. Asymptomatic infections 
can occur in 10% of cases, which is suggested through skin 
hypersensitivity tests.
27
 
A wide variety of manifestations may occur, which 
can be attributed to variation in parasite virulence and host 
defense. Cutaneous manifestations associated with 
Leishmania may be: 
Localized Cutaneous Leishmaniasis: Lesions usually 
occur on exposed areas of the skin and begin as a papule that 
becomes a lump, progressing to a painless ulcer with 
indentation at the edges and granulomatous fundus. Multiple 
lesions may be present and regional lymphadenopathy may 
occur. Secondary bacterial infections can be associated with 
the lesions. Their healing can take from months to years, 
depending on the size and the species involved, and this scar 
can become atrophic, with areas of hypo or 
hyperpigmentation or even keloid, in a patient with such 
predisposition.
28
 
There are some clinical differences between species, 
but there may also be overlapping between them. The most 
common are: L. infantum chagasi, L. braziliensis and L. 
guyanensis.
29
 
Diffuse or Disseminated Cutaneous Leishmaniasis: It 
is a rare form and usually occurs with the involvement of L. 
amazonensis and L. Braziliensis.
29
 It begins with a lesion that 
does not ulcerate, and then amastigotes spread to 
macrophages in other regions, probably via blood or lymphatic 
vessels. Histologically, many parasites are visualized, but with 
little lymphocytic reaction. These patients often have a defect 
in cellular immunity, which makes treatment more difficult. 
Another important characteristic of this form is that it can 
occur concomitantly to mucosal involvement and systemic 
symptoms, such as fever and emaciation.
28
 
Mucosal Leishmaniasis: It is characterized by mucosal 
destruction, deformities, pain and inflammation. Erosion can 
occur, most commonly in the mouth and nasal septum, and 
may involve other areas such as pharynx, ment and palate. 
Recurrent form: The reactivation of the localized 
lesion occurs mainly in its borders.
29
 
The definitive diagnosis can be made through direct 
investigation of the lesion through the scraping of the borders, 
culture of fragments obtained by biopsy, histopathology with 
visualization of amastigotes, PCR, serology and immunology 
(Intradermic Reaction of Montenegro) tests.
29
 
Differential diagnosis includes bacterial infections, 
ecthyma, impetigo, sarcoidosis, lichen simplex, and fungal 
infections such as sporotrichosis, blastomycosis and 
chromoblastomycosis. Some characteristics that help 
differentiate it from other diseases are its chronicity, 
occurrence in exposed areas of the skin and ulcer with well-
defined enduring edges. 
Because of the rapid or late establishment of a 
specific immune response that leads to the parasite 
elimination, some individuals may have early lesion healing, 
sometimes without seeking medical attention, while others 
may remain for months with the lesion active and with a slow 
healing process.
29
 
Pentavalent antimonials are the drugs of first choice 
in the treatment of cutaneous leishmaniasis. Meglumine 
antimonate is the formula available in Brazil. It should be 
administered at a dose of 10 to 20 mg Sb
+5
/kg/day, with a 
maximum dose of 15 ml/day for 20 days. For the mucosal 
lesions, the treatment should last 30 days. It is contraindicated 
for pregnant women, patients with cardiac, kidney or liver 
disease and Chagas disease. If there is no satisfactory 
response or in the presence of contraindications, the second-
choice drug is amphotericin B deoxycholate 0,7 to 1 
mg/kg/day, with a total dose of 25 to 40 mg/kg, not exceeding 
the maximum daily dose of 50 mg in each application. It is 
contraindicated in patients with liver, renal or cardiac 
diseases. As a last resource, when attempts with other drugs 
have failed or there are contraindications, liposomal 
amphotericin B may be used, 2 to 5 mg/kg/day, depending on 
the clinical response, until reaching a total of 25 to 40 mg/kg.
29
 
In the case presented, liposomal amphotericin B was 
the drug of choice for treatment due to the comorbidities 
presented by the patient, besides his age. The patient used 
1900 mg of the medication, reaching a total of 15.8 mg/kg. 
The total dose was therefore below the goal recommended by 
the Health Ministry. However, due to a new direct 
parasitological test of the lesion with a negative result, and 
good cicatricial response, the patient was discharged. 
The healing criterion of ATL is clinical, and regular 
follow-up during 12 months is indicated to verify the 
therapeutic response and the possibility of relapse after 
successful initial therapy. The case is considered as cured after 
complete epithelization of all lesions, which should occur 
within 90 days after the completion of the treatment regimen, 
and disappearance of crust, scaling, infiltration and erythema 
up to the 180th day.
29
 Therefore, the patient still cannot be 
considered cured and, for this reason, outpatient follow-up 
will be necessary.  
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CONCLUSION 
 
Amphotericin B is already a consolidated therapeutic 
alternative in cases of ATL, especially in patients who have 
restrictions concerning the use of pentavalent antimonials. 
However, CMB is still a therapeutic challenge and, in clinical 
practice, a great resistance to the most frequently used 
antifungal agents is observed. Therefore, the combined use of 
drugs is an effective alternative. 
In the present case, although the patient was initially 
using the standard therapy for treatment of CMB, with 
itraconazole associated with terbinafine and cryotherapy, this 
strategy only achieved stabilization of the lesions, according to 
the report. Given the need to also treat ATL lesions, we could 
notice a significant improvement in CMB lesions with the use 
of amphotericin B in combination with itraconazole. However, 
despite the beneficial effect of the use of amphotericin B, the 
patient's renal status prevented the prolonged treatment with 
this drug. 
. 
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Chromoblastomycosis. Postȩpy Dermatol Alergol 2014; 
31: 310-21 
20. Subhadarshani S, Yadav D. Dermoscopy of 
chromoblastomycosis. Dermatol Pract Concept 2017; 
7(4): 23-24. 
21. Tanuma H, Hiramatsu M, Mukai H, Abe M, Kume H, 
Nishiyama S, Katsuoka K. Case report. A case of 
chromoblastomycosis effectively treated with 
terbinafine. Characteristics of chromoblastomycosis in 
the Kitasato region, Japan. Mycoses. 2000; 43:79 – 83 
22. Esterre P, Inzan CK, Ramarcel A, Andriantsimahavandy M, 
Ratsioharana M, Pecarrere JL, Roig P.  Treatment of 
chromomycosis with terbinafine: preliminary results of 
an open pilot study. Br J Dermatol. 1996; 134(Suppl 46): 
S33–S36 
23. Bonifaz A, Saúl A, Paredes-Solis V, Araiza J, Fierro-Arias L. 
Treatment of chromoblastomycosis with terbinafine: 
experience with four cases. J Dermatol Treat, 2005, 
16:47–51 
24. Daboit TC et al.In vitro susceptibility of 
chromoblastomycosis agents to five antifungal drugs and 
to the combination of terbinafine and amphotericin 
B.Mycoses, 2014, 57, 116–120 
25. Alva ZB. Cromomicosis: clínica y tratamiento; situación 
epidemiológica en latinoamérica. Rev Peru Med Exp 
Salud Publica 21(3), 2004 
26. Queiroz-Telles F et al. Chromoblastomycosis. Clinical 
microbiology reviews, v. 30, n. 1, p. 233-276, 2017. 
27. Follador I, Araújo C, Bacellar O, Araújo CB, Carvalho LP, 
Almeida RP, Carvalho. Epidemiologic and immunologic 
Revista de Patologia do Tocantins  2018; 5(1): 46-52.                             DOI: 10.20873/uft.2446-6492.2018v5n1p46 
Resstel et al. 
 
52 
 
Revista de Patologia do Tocantins, Vol. 5 No. 1, Abril 2018 
 
findings for the subclinical form of Leishmania 
braziliensis infection. Clin Infect Dis. 2002 
Jun;34(11):E54-8. Epub 2002 May 7. Acesso em 12 -01-
18. 
28. Dowlati Y. Cutaneous leishmaniasis: clinical aspect. Clin 
Dermatol. 1996 Sep;14(5):425-31. Acesso em 12-01-18. 
29. Ministério Da Saúde, Secretaria de Vigilância em Saúde. 
Manual de Vigilância da Leishmaniose Tegumentar. 
Brasília, DF, 2017.  
